


JOHN HOFFMAN  
ACTING ATTORNEY GENERAL OF NEW JERSEY  
Division of Law - 5<sup>th</sup> Floor  
124 Halsey Street  
P.O. Box 45029  
Newark, New Jersey 07101  
Attorney for the Board of Pharmacy

By: Megan Cordoma  
Deputy Attorney General  
Tel. No. (973)648-4735



STATE OF NEW JERSEY  
DEPARTMENT OF LAW & PUBLIC SAFETY  
DIVISION OF CONSUMER AFFAIRS  
STATE BOARD OF PHARMACY

IN THE MATTER OF THE SUSPENSION :  
OR REVOCATION OF THE LICENSE OF :  
  
**Karen P. Littman, R.P.** :  
License No.28RI01642300 :  
:  
TO PRACTICE PHARMACY IN THE :  
STATE OF NEW JERSEY :

Administrative Action

**CONSENT ORDER  
OF REINSTATEMENT**

This matter was opened to the New Jersey State Board of Pharmacy (“The Board”) upon receipt of Respondent Karen Littman’s application for reinstatement of her license to practice pharmacy in the State of New Jersey. By way of history, on November 19, 2009, Respondent was subject to a Final Order of Discipline suspending her license to practice pharmacy in the State of New Jersey pursuant to N.J.S.A. 45:1-21(g), based on having had her authority to engage in the activity regulated by the Board

suspended by another state for reasons consistent with N.J.S.A. 45:1-21. Specifically, by Order filed on June 5, 2009, the Ohio State Board of Pharmacy ("The Ohio Board") suspended Respondent's license to practice pharmacy based on allegations of drug addiction and abuse, procuring prescriptions for CDS by deception, possessing false or forged prescriptions, and making false statements on her Ohio license renewal application pertaining to her conviction for theft.

By Order effective January 17, 2012, Respondent's Ohio license was both reinstated and placed on probation for ten (10) years beginning January 17, 2012. Conditions of the Ohio reinstatement include but are not limited to a requirement that Respondent enter into a new contract with an Ohio Department of Alcohol and Drug Addiction Services (ODADAS) Treatment Provider or other Treatment Provider approved by the Ohio Board (hereinafter "Treatment Provider") for a period of not less than five years; undergo random, observed urine drug screens at least once each month for the first year and then at least once every three months for the remaining four years; and attend support group meetings at least three times a week while under supervision of the Treatment Provider.

Respondent, being desirous of resolving this matter without the necessity of further formal proceedings, and agreeing to waive any right to same, and the Board having determined that this Order is sufficiently protective of the public health, safety and welfare, and all parties agreeing to the terms of this Order;

**ACCORDINGLY, IT IS** on this 12<sup>th</sup> day of January, <sup>2015</sup>~~2014~~,  
**ORDERED THAT:**

1. Respondent's license shall be reinstated following her provision to the Executive Director of the Board of the following which shall all be to the satisfaction of the Board:

- a. Proof of successful completion of all application requirements including a criminal history background check with results that are satisfactory to the Board, and payment of all reinstatement fees;
- b. Documentation of completion of continuing education credits required by N.J.A.C. 13:39-3A.1 to 13:39-3A.7.

2. After Respondent has complied with all of the requirements of paragraph (1) of this Order to the satisfaction of the Board, Respondent's license to practice pharmacy shall be reinstated subject to the conditions in paragraphs three to ten of this Order.

3. Respondent's license shall be placed on probation for a period of ten (10) years retroactive to January 17, 2012 and to run concurrent with the probationary period determined by the Ohio Board of Pharmacy and until further Order of this Board. Respondent shall alert the Board to any and all changes in status of her Ohio license within 10 days of each such change.

4. During the period of probation, Respondent shall not act as a preceptor or pharmacist-in-charge (RPIC) at any pharmacy, shall not own or have an ownership interest in any pharmacy, shall not engage in the training of pharmacy interns, and shall not destroy, assist in, or witness the destruction of CDS.

5. During the period of probation, Respondent shall comply with all the terms and conditions imposed by the Ohio Board Order dated January 17, 2012.

6. During the period of probation, a copy of this Order shall be provided to all employers where a pharmacy license is required for employment or where the Respondent has access to medication, prescriptions or patient profiles. The Respondent shall ensure that each employer notifies the Board in writing that he or she has received this Order prior to Respondent beginning employment.

The Respondent shall inform the Board in writing of any employment changes, including periods of unemployment, and shall also provide a detailed description of her job, role and responsibilities.

7. Respondent shall continue to enroll in and comply fully with the monitoring program established for her by a Treatment Provider, for a minimum of the first five years of her probation consistent with her Ohio Order and until such time as the Ohio Board determines that her enrollment in the monitoring program is no longer required. Such monitoring program shall include but not be limited to:

- a. Absolute abstinence from all psychoactive substances including alcohol unless prescribed by a treating health care professional aware of her substance abuse history for a documented medical condition. Respondent shall advise all of her treating health care practitioners, who prescribe medications, of her addiction history. Respondent shall be responsible for providing documentation to her Treatment Provider from her health care practitioner indicating diagnosis and treatment regimen, including a copy of prescriptions for psychoactive substances within five days issuance of the prescription. Respondent shall be responsible to request that the treating health care professional release and provide necessary supporting documentation to the Treatment Provider upon request by the Treatment Provider to ensure compliance.
- b. Respondent shall attend support group meetings of Narcotics Anonymous and/or Alcoholics Anonymous at a frequency of not less than three meetings per week. Respondent shall provide evidence of attendance at such groups directly to her Treatment Provider, on a form or in a manner as required by that Treatment Provider.
- c. Respondent shall undergo witnessed urine monitoring under the supervision of her Treatment Provider, on a random, unannounced basis, at a frequency of no less than once per month for the first year following Respondent's enrollment in the drug treatment program, and no less than once every three months for the next four years during Respondent's participation in the program. Subsequent reductions in the frequency of urine screens shall be at the direction of the Treatment Provider consistent with Respondent's duration in recovery with prior written notification from the Treatment Provider to the State Board of Pharmacy. All test results shall be provided in the first instance directly to the applicable Treatment Provider and any positive result shall be reported immediately by that Treatment Provider to the Executive Director of the New Jersey Board. Correspondence to the executive director of the Board Of Pharmacy via e-mail to: [RubinaccioA@dca.lps.state.nj.us](mailto:RubinaccioA@dca.lps.state.nj.us) shall constitute an alternative acceptable written

notification to postal mail

- d. The Board reserves the right to require a modification of the manner of the random witnessed urine testing by the Treatment Provider in the event technical developments or individual requirements indicate that a different methodology or approach is required to guarantee the accuracy and reliability of the testing.
- e. Respondent's failure to submit to or provide a urine sample within twelve hours of a request shall be deemed to be the equivalent of a confirmed positive urine test and shall be deemed a violation of this order unless Respondent is unable to appear for a scheduled urine test due to illness or other impossibility. Respondent must advise the Board in writing within two (2) days, and request that the Treatment Provider also so advise the Board in writing within (2) days, of a claimed illness or impossibility. Correspondence to the executive director of the Board of Pharmacy via e-mail to: [RubinaccioA@dca.lps.state.nj.us](mailto:RubinaccioA@dca.lps.state.nj.us) shall constitute an alternative acceptable written notification to postal mail. If Respondent fails to appear for a scheduled urine test due to illness, Respondent shall provide to the Board, written substantiation of the illness in the form of a physician's report, within two (2) days. "Impossibility" means an obstacle beyond the control of Respondent that is insurmountable or that makes her appearance for the urine test so infeasible that a reasonable person would waive Respondent's requirement to give the urine sample that day
- f. All random witnessed alcohol and drug screens shall be negative for the presence of alcohol or drugs, unless the drugs detected by screening were taken for a documented illness pursuant to a valid prescription from a health care practitioner aware of Respondent's substance abuse history. All positive results shall be confirmed by the Gas Chromatography Mass Spectrometry (GC/MS) testing method. Chain of custody documentation must accompany all laboratory reports and/or the laboratory reports must indicate that chain of custody procedures have been followed.
- g. Any urine test result showing creatinine levels below 20 mg/dl and a specific gravity below 1.003 shall create a rebuttable presumption of a confirmed positive urine test, and shall be followed by a confirming test. The method of the confirming test shall be determined by the Treatment Provider.
- h. Respondent shall become familiar with all foods, food additives or other products (such as poppy seeds) which may affect the validity of urine screens, be presumed to possess that knowledge, and shall refrain from the use of such substances. Respondent specifically agrees that ingestion of such substances shall not be an acceptable reason for a positive urine screen and/or failure to comply with the urine monitoring program.

- i. Respondent shall be responsible to ensure that her Treatment Provider shall supply reports to the Board every ninety (90) days beginning on the "filed" date of this Order regarding her progress with the monitoring program.
- j. Respondent shall obtain the agreement of the Treatment Provider via a signature of its representative on this Order to notify the Board within 24 hours of its receipt of information of any noncompliant behavior, slip or relapse of impairment, including but not limited to any positive urine screen or failure to appear for urine monitoring or any scheduled appointment or any discontinuance of the approved rehabilitation program whether initiated by Respondent or by the Treatment Provider.
- k. Respondent expressly waives any claim to privilege or confidentiality that she may have concerning reports and disclosures to the Board, and use by the Board of that information in any license proceedings, including reports and disclosures by the urine monitoring program, or the Treatment Provider, or any other person or entity involved in her rehabilitation program.
- l. All costs associated with the monitoring outlined above shall be the responsibility of, and paid directly by, Respondent.

8. Nothing in this Order shall be deemed to preclude the Board from taking any action it deems appropriate should the Board's review of information cause it to determine that such action is warranted or from imposing restrictions or conditions on Respondent's license should the Board determine that such restrictions or conditions are appropriate to protect the public health, safety, and welfare.

9. Failure to comply with any of the terms of the Ohio Order shall be deemed a violation of this Consent Order and may result in further disciplinary action.

10. Failure to comply with any of the terms of this Consent Order may result in further disciplinary action.

NEW JERSEY STATE BOARD OF PHARMACY

By: Thomas F.X. Bender, Jr., R.Ph.  
Thomas F.X. Bender, R.P.,  
President

I have read the within Order and understand its terms. I consent to the entry of this Order by the New Jersey Board of Pharmacy.

Karen P. Littman  
Karen P. Littman, R.P.

I agree to the monitoring and reporting requirements specified above on behalf of the Treatment Provider approved by Ohio Department of Alcohol and Drug Addiction Services or the Ohio Board of Pharmacy:

Jarrod Grossman  
Name: Jarrod Grossman  
Title: Executive Director  
Organization: PNO, Inc